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hemorrhagic fever—randomized trials are
urgently needed
The only antiviral drug used today in Crimean-Congo hemor-
rhagic fever (CCHF) is ribavirin; however, its efﬁcacy is controver-
sial due to the lack of randomized controlled trials.
The studies examining the efﬁcacy of ribavirin in CCHF have
generally been retrospective studies including insufﬁcient num-
bers of patients, resulting in low power. We think that ribavirin
should not be used in CCHF until randomized controlled studies
have been conducted, and that only supportive treatment should
be used.1
In response to the letter from Professor Onder Ergonul
suggesting that our conclusions are wrong, we provide the
scientiﬁc evidence outlined below.
First, Professor Ergonul suggests that a study published in
2013 showed ribavirin to decrease the mortality from CCHF.2
However, in that retrospective study, the patients were grouped by
severity as mild, moderate, and severe cases, and ribavirin
decreased mortality only in moderate cases. It was reported that
two of 134 cases receiving ribavirin and three of 18 cases not
receiving ribavirin died, and that this difference was statistically
signiﬁcant. The mortality rates were low in the ribavirin group, but
because the study was not randomized, the patient selection may
have been biased; for example, severe cases may not have received
ribavirin if this drug was not available at the hospital of admission
and then died before it became available or after just a few doses.
Therefore, we believe that the study result showing the decreased
mortality in the ribavirin group is due to a type 1 error.
Second, Professor Ergonul suggests that some studies per-
formed recently in Turkey have revealed as an outcome that
ribavirin decreased mortality in CCHF.2–5 One of these studies is
related to healthcare employees coming into contact with the
CCHF virus or being infected following CCHF exposure.4 In that
study, nine healthcare employees were administered ribavirin
following injury with contaminated tools, two before any
symptoms developed and seven after they had developed
symptoms. It was suggested that the development of CCHF-
related symptoms was prevented in two healthcare employees
coming into contact with the CCHF virus. However, CCHF is a
disease with a high probability of asymptomatic presentation,
thus this invalidates that comment. Additionally, stating that
ribavirin is effective in CCHF based on only two cases does not
coincide with scientiﬁc study principles. Further, in that study,
ribavirin was administered to seven healthcare employees
developing CCHF, and it was reported that only one case died.
When these seven study cases are examined in detail, it is
observed that four cases were of moderate severity, two of mild
severity, and one was of severe grade – the healthcare worker who
died was the severe grade case. Therefore, it is more probable thathttp://dx.doi.org/10.1016/j.ijid.2014.08.015
1201-9712/ 2014 Published by Elsevier Ltd on behalf of International Society for Infect
creativecommons.org/licenses/by-nc-nd/3.0/).survival is related to disease severity rather that the use of
ribavirin.
In another study, mortality was found to be 0% in eight cases
receiving ribavirin and 4.5% in 22 severe cases (one patient died)
who did not receive ribavirin; it was claimed that mortality was
much higher in the patients not receiving ribavirin.5 However, the
difference between the groups was not statistically signiﬁcant and
the patients were not randomized prospectively.
Professor Ergonul suggests that ribavirin use in CCHF is
supported by two other studies included in our article.6,7 However,
these studies did not ﬁnd that ribavirin reduced mortality, only
that some laboratory parameters improved more rapidly in
patients receiving ribavirin.
Professor Ergonul indicates that the study reported in a
reference we cited was biased and that an editorial has been
published in relation to this subject.8,9 He further suggests that
there was a bias in that study arising from ribavirin administration
to more severe cases. However, it is known that clinicians in Turkey
in 2004, the year in which the study was performed, administered
ribavirin to all cases, without differentiating between mild and
severe ones.
Third, in the only randomized controlled study examining the
efﬁcacy of ribavirin in CCHF, no statement about the recruitment of
only late cases is available as suggested by the author.10 In our
opinion the only deﬁcient aspect of this study was that the effect of
ribavirin on mortality was not examined in the groups in which the
cases were separated into early and late cases.
Professor Ergonul suggests that the conduct of a study
examining the efﬁcacy of ribavirin in CCHF is in contravention
to the Declaration of Helsinki. This Declaration ﬁnds the
administration of placebo to a group of patients to be inappropriate
when a treatment method of proven beneﬁt in a disease is
available. However, it is our ﬁrm belief that the efﬁcacy of ribavirin
in CCHF is not proven, and on the contrary it has been
demonstrated in many non-randomized, retrospective studies
and case series that it has no effect on mortality. Therefore, we
think that it is ethically acceptable to perform a randomized,
placebo-controlled study in CCHF in relation to ribavirin use,
stratifying for disease stage. Furthermore, ribavirin usage rates
have decreased to 11.8% in Turkey according to the 2004–2007
data of the Turkish Ministry of Health, Department of Zoonotic
Diseases, as reported by Ceylan et al.1 and Turhan et al.11 In other
words, the drug is no longer used in the treatment of the disease.
Fourth, Professor Ergonul has suggested that in a study on the
early administration of ribavirin in CCHF the mortality rate
was 2.9% (10/342) and that this rate was lower than the rate of
5% (20/400) reported in another study in which the cases were not
administered ribavirin.3,12 In the study mentioned, the cases using
ribavirin were not grouped as early and late cases, and early- and
late-presenting cases were not compared in terms of mortality, in
fact all cases were accepted as early applying cases; nevertheless itious Diseases. This is an open access article under the CC BY-NC-ND license (http://
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early phase.
Fifth, Professor Ergonul has attributed the demonstration of
higher mortality in the ﬁrst 8 days of patients receiving ribavirin
compared to patients not receiving ribavirin to the clinicians’
preference for the initiation of ribavirin administration only
in severe cases.8 However, as it is known that in 2004, the year in
which the study was conducted in our country, ribavirin
administration was initiated for every case regardless of disease
severity, this comment is not valid.
It is clear that the studies in relation to ribavirin use in CCHF
are insufﬁcient and conﬂicting. We think that the persistent
recommendation of a drug of unproven efﬁcacy for a particular
disease may mislead the physicians involved with this disease.
Furthermore ribavirin has severe side effects, and the effects and
side effects need to be balanced.
Therefore, we think that until ribavirin use in patients with
CCHF has been clariﬁed by a randomized controlled trial, it is
appropriate to monitor patients using supportive treatment only.
The use of ribavirin should be restricted to patients included in
a study protocol.
We believe that performing a prospective, randomized,
placebo-controlled study of ribavirin in CCHF is ethically accept-
able and urgently needed.
Conﬂict of interest: No conﬂict of interest to declare.
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